|
|
36 East Industrial Road
Branford, CT 06405 USA
phone:(203) 315-1222
fax:(203) 488-7838 |
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.cellulargenomics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Small molecule kinase inhibitors. |
|
| Management |
| David Armistead, Ph.D., Chief Scientific Officer; Peter Fuller, Ph.D., Chief Operating Officer; Muzammil Mansuri, Ph.D., chairman & Acting CEO; Mark Velleca, M.D., Ph.D., Founder & Senior Vice-President |
|
|
| |
| Keywords |
| small molecule, kinase inhibitor, oncology, angiogenesis, autoimmune, Allergy, allergies, allergic, inflammatory, AllergyImmunology |
|
|
|
|
|
| Description |
|
CGI Pharmaceuticals is focused on the discovery and development of breakthrough small molecule kinase inhibitors for a broad range of oncology/angiogenesis and autoimmune/allergic/inflammatory disease indications. |
|
| Products / Services |
Btk, Bruton's tyrosine kinase, is a novel, highly attractive target for the treatment of multiple autoimmune/allergic/inflammatory diseases, including rheumatoid arthritis (RA), Systemic Lupus Erythematosus (SLE), and asthma. Expressed in B-cells, mast cells, and monocytes, Btk has been shown to be essential for the activation of inflammatory pathways through the B-cell receptor
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members